# A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

> **NCT05938270** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 120 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Saruparib (AZD5305)
- **DRUG:** Darolutamide
- **OTHER:** No Treatment

## Key facts

- **NCT ID:** NCT05938270
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2026-08-17
- **Final completion:** 2026-08-17
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938270, "A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05938270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*